IGNITE update - Eight hospitals have been enrolled in the program

IGNITE update - Eight hospitals have been enrolled in the program

The enrollment of hospitals in the IGNITE program - 2cureX initiative to speed up the adoption of IndiTreat® - is progressing as planned. As of today, eight hospitals from five different countries have joined the program

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, present today an update on its IGNITE program, which is progressing according to plan. Eight hospitals from five different countries have already been enrolled and eight additional hospitals, including two additional countries, are in advanced discussions.

2cureX had previously announced the goal of having twelve hospitals enrolled in the IGNITE program by the end of Q2, and had defined a goal of reaching 20 countries and 30 hospitals using IndiTreat® by the end of 2022 (Strategy Update, October 12th).

IGNITE stands for “Inducing Growth through a Network of IndiTreat Evaluations” and is a program the company launched in 2021 to accelerate the uptake of IndiTreat® in hospitals across Europe. Hospitals participating in IGNITE get a limited number of patients tested with IndiTreat® at no cost, in exchange for sharing their results at conferences and scientific events. The aim is to facilitate the introduction of the new technology and create a critical mass of users as quickly as possible.

Expecting an acceleration in the recruitment of new hospitals

“The IGNITE program has been very well received in the market”, says Fernando Andreu, CEO of 2cureX. “Having eight hospitals already enrolled is a testimony to the interest of oncologists in IndiTreat®. It takes a while to get everything in motion, but we are on track, and with our distributor’s sales teams now fully trained and ready, we expect an acceleration in the recruitment of new hospitals going forward”.

Building a critical mass of early users

Jesper Floyd Kristiansen, VP Business Development of 2cureX: “IGNITE is a great tool for the sales teams to engage with oncologists. When launching a new technology that is not yet in guidelines, building a critical mass of early users is fundamental. Sharing their experience, these early users become a reference for the rest, creating a network effect. We are confident we will fulfill our plans for 2022”.

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The portfolio of IndiTreat® tests is aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® mCRC Start for first line of therapy, IndiTreat® mCRC Extend and IndiTreat® mCRC Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
 
Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se